نتایج جستجو برای: hiv vaccine

تعداد نتایج: 309384  

2013
Kathryn E Stephenson Dan H Barouch

A global human immunodeficiency virus-1 (HIV-1) vaccine will have to elicit immune responses capable of providing protection against a tremendous diversity of HIV-1 variants. In this review, we first describe the current state of the HIV-1 vaccine field, outlining the immune responses that are desired in a global HIV-1 vaccine. In particular, we emphasize the likely importance of Env-specific n...

2014
Cheryl Cohen Claire von Mollendorf Linda de Gouveia Nireshni Naidoo Susan Meiring Vanessa Quan Vusi Nokeri Melony Fortuin-de Smit Babatyi Malope-Kgokong David Moore Gary Reubenson Mamokgethi Moshe Shabir A. Madhi Brian Eley Ute Hallbauer Ranmini Kularatne Laura Conklin Katherine L. O'Brien Elizabeth R. Zell Keith Klugman Cynthia G. Whitney Anne von Gottberg Charl Verwey Sheeba Varughese Moherndran Archary Fathima Naby Khathija Dawood Ramola Naidoo Gene Elliott Ute Hallbauer Brian Eley James Nuttall Louise Cooke Heather Finlayson Helena Rabie Andrew Whitelaw Dania Perez Pieter Jooste Dhamiran Naidoo Ranmini Kularatne Gary Reubenson Cheryl Cohen Linda de Gouveia Mignon du Plessis Nevashan Govender Susan Meiring Vanessa Quan Claire von Mollendorf Melony Fortuin-de Smidt Nireshni Naidoo Babatyi Malope-Kgokong Vusi Nokeri Relebohile Ncha Sonwabo Lindani Anne von Gottberg Barry Spies Lino Sono Phasweni Maredi Ken Hamese Mamokgethi Moshe Maphosane Nchabeleng Ntombenhle Ngcobo Johann van den Heever Shabir Madhi Laura Conklin Jennifer Verani Cynthia Whitney Elizabeth Zell Jennifer Loo George Nelson Keith Klugman Katherine O'Brien

BACKGROUND South Africa introduced 7-valent pneumococcal conjugate vaccine (PCV7) in April 2009 using a 2 + 1 schedule (6 and 14 weeks and 9 months). We estimated the effectiveness of ≥2 PCV7 doses against invasive pneumococcal disease (IPD) in human immunodeficiency virus (HIV)-infected and -uninfected children. METHODS IPD (pneumococcus identified from a normally sterile site) cases were id...

2013
Zhenxing Chu Junjie Xu Kathleen Heather Reilly Chunming Lu Qinghai Hu Ning Ma Min Zhang Jing Zhang Yongjun Jiang Wenqing Geng Hong Shang

BACKGROUND The number of new HIV infections among MSM of China is rapidly increasing in recent years and behavioral interventions have had limited effectiveness. To control the HIV pandemic may lie in an HIV vaccine. This study examined the factors associated with willingness to participate (WTP) in HIV vaccine clinical trials among China MSM. METHODS A cross-sectional survey was carried out ...

2015
Hai-Bo Wang Qiu-Hua Mo Ze Yang

Human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) is a worldwide epidemic, with over 35 million people infected currently. Therefore, the development of a safe and effective HIV-1 vaccine is on top of the global health priority. In the past few years, there have been many promising advances in the prevention of HIV/AIDS, among which the RV144 Thai trial has been encour...

2016
Nishila Moodley Glenda Gray Melanie Bertram

Despite comprising 0.7% of the world population, South Africa is home to 18% of the global human immunodeficiency virus (HIV) prevalence. Unyielding HIV subepidemics among adolescents threaten national attempts to curtail the disease burden. Should an HIV vaccine become available, establishing its point of entry into the health system becomes a priority. This study assesses the impact of school...

Journal: :modares journal of medical sciences: pathobiology 2010
mehdi mahdavi massoumeh ebtekar kayhan azadmanesh fereidoun mahboudi hamidreza khorramkhorshid

objective: several vaccines against hiv have been investigated but none has been approved as an effective hiv vaccine. an approach that could induce stronger immune response against the pathogen is utilizing a multi-epitopic vaccine. this strategy was used in the design of several vaccines and resulted in improved immune responses. materials and methods: in this study a multi-epitopic fusion p...

2017
Joseph N. Inungu Bonnie Bender Lisa Gieber

Introduction: Social and behavioral factors have the potential to affect and inform both the implementation of HIV vaccine trials and the uptake of an eventual HIV vaccine. The growing number of ongoing phase I/II HIV vaccine trials underscores the need for a review of factors affecting the conduct of these trials. Methods: Major databases (PubMed, Cochrane, and Google Search Engine) were searc...

Journal: :Immunity 2010
M Juliana McElrath Barton F Haynes

Recent findings have brought optimism that development of a successful human immunodeficiency virus type-1 (HIV-1) vaccine lies within reach. Studies of early events in HIV-1 infection have revealed when and where HIV-1 is potentially vulnerable to vaccine-targeted immune responses. With technical advances in human antibody production, clues about how antibodies recognize HIV-1 envelope protein...

2009
Marie-Eve Blais Sarah Rowland-Jones

The much-publicised halting of the joint Merck/HIV Vaccine Trials Network phase IIB candidate HIV-1 vaccine trial in 2007 has led to an unprecedented degree of discussion and introspection amongst the HIV research community. In this commentary, we will summarise the lessons learned from the trial and examine the current state of HIV vaccine research.

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2014
Haitao Hu Michael A Eller Shah Zafar Yu Zhou Mengnan Gu Zhi Wei Jeffrey R Currier Mary A Marovich Hannah N Kibuuka Robert T Bailer Richard A Koup Merlin L Robb Nelson L Michael Jerome H Kim Silvia Ratto-Kim

Efficacy trials of adenovirus 5-vectored candidate HIV vaccines [recombinant Ad5 (rAd5)-HIV] were halted for futility due to lack of vaccine efficacy and unexpected excess HIV infections in the vaccine recipients. The potential immunologic basis for these observations is unclear. We comparatively evaluated the HIV susceptibility and phenotypes of human CD4 T cells specific to Ad5 and CMV, two v...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید